Status:
UNKNOWN
Single Fraction HDR Brachytherapy Plus Hypofractionated EBRT for Low-risk Prostate Cancer: Phase II Trial
Lead Sponsor:
AC Camargo Cancer Center
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18-90 years
Phase:
PHASE2
Brief Summary
The hypofractionated external radiation (EBRT) is a technique that radiation dose delivery using higher daily fractions than those used routinely. In this way can cause more damage tumor, especially i...
Detailed Description
OBJECTIVE The primary objective is to analyze the toxicity profile, via a phase II study of treatment of patients with low risk prostate cancer with the association of hypo fractionated EBRT and HDR b...
Eligibility Criteria
Inclusion
- Biopsy confirming adenocarcinoma of the prostate
- Low-risk Prostate Cancer: less than or equal T2a stage + PSA less than or equal to 10 ng/ml stage + Gleason score less than or equal to 6
- Prostate volume than or equal to 60cc
Exclusion
- Adjuvant Hormone
- Prior pelvic radiotherapy
- Adjuvant Chemotherapy
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02283346
Start Date
November 1 2014
End Date
November 1 2017
Last Update
November 5 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AC Camargo Cancer Center
São Paulo, São Paulo, Brazil, 01509-010